Detailed Information

Cited 0 time in webofscience Cited 2 time in scopus
Metadata Downloads

A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16)open access

Authors
Byun, Sang JunPark, WonCho, Kwan HoCho, JaehoChang, Ah RamKang, Ki MunKim, Jin HoKim, Jin Hee
Issue Date
17-Jan-2019
Publisher
Public Library of Science
Keywords
bladder cancer; radiotherapy
Citation
PLoS ONE, v.14, no.1
Journal Title
PLoS ONE
Volume
14
Number
1
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4786
DOI
10.1371/journal.pone.0209998
ISSN
1932-6203
Abstract
Background Although radical cystectomy is a standard treatment in muscle-invasive bladder cancer, bladder preservation therapy including transurethral resection of bladder tumor, radiotherapy, and concurrent chemotherapy has been widely adopted, recently. This retrospective analysis was performed to evaluate the survival rates and prognostic factors related to treatment outcomes following bladder-preserving therapy including radiotherapy (RT) in bladder cancer with a curative intent. Materials and methods We conducted a multi-institutional retrospective study of 152 patients with stage II-IV bladder cancer treated with curative RT between 2000 and 2010. There were 72 patients in stage II, 49 in stage III, and 31 in stage IV. Ninety-seven patients were treated with concurrent chemoradiotherapy and fifty-five with RT alone. Radiation was delivered to the pelvis (median 63 Gy), mainly with cisplatin. The median follow-up time was 35.5 months. Results Sixty-nine patients (45.4%) showed a complete response to RT. The 5-year overall survival (OS) rate was 45.8%, the 5-year cause-specific survival (CSS) rate was 48.9%, and the 5-year disease-free survival (DFS) rate was 20.8%. Univariate analysis revealed significant differences in the following factors according to the survival rates: patient age, initial hemoglobin level, clinical T stage, clinical N stage, clinical stage group, tumor response to RT, hydronephrosis, and concurrent chemotherapy. Multivariate analysis also revealed a significant difference in patient age (p = 0.003 in OS, p<0.017 in CSS) and tumor response to RT (p = 0.002 in OS, p<0.001 in CSS). Concurrent chemotherapy was significantly different in the DFS rates (p = 0.046). Conclusions The survival rates reported herein are comparable to those from other studies, and tumor response and concurrent chemoradiotherapy were significant prognostic factors for better survival rates. Further randomized studies are needed to elucidate the impact of RT in bladder cancer.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Radiation Oncology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Chang, Ah Ram photo

Chang, Ah Ram
College of Medicine (Department of Radiation Oncology)
Read more

Altmetrics

Total Views & Downloads

BROWSE